François Ghiringhelli

Immunology · 2004–2021

A researcher in the Science corpus: 18 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 242 citations into it; #696 of 2,160 by trust here, #72 by citations

Whom François Ghiringhelli trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Shimon Sakaguchi
2. E. Shevach
3. P. Matzinger
4. A. Diefenbach
5. D. Gabrilovich

Who trusts François Ghiringhelli overall

1. L. Zitvogel
2. L. Galluzzi
3. Guido Kroemer
4. S. Formenti
5. Oliver Kepp
6. F. Di Virgilio
7. A. Mantovani
8. F. Balkwill
9. S. Demaria
10. C. Garlanda

Papers from François Ghiringhelli's perspective

Ordered by how strongly the researchers François Ghiringhelli trusts endorse each paper. Same corpus, a different order for every researcher.

1. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells (Science)
2. Gout-associated uric acid crystals activate the NALP3 inflammasome (Nature)
3. Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo (Nature Immunology)
4. Cryopyrin activates the inflammasome in response to toxins and ATP (Nature)
5. Interactions between the microbiota and the immune system (Science)
6. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. (Immunity)
7. The Danger Model: A Renewed Sense of Self (Science)
8. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells (Immunity)
9. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response (Nature)
10. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (Nature Medicine)

Their papers

• The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide (2013) — 1,872 citations
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2018) — 4,955 citations
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors (2009) — 1,892 citations
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death (2005) — 1,431 citations
• Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. (2010) — 959 citations
• Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth (2012) — 726 citations
• Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy (2021)
• Consensus guidelines for the detection of immunogenic cell death (2014) — 787 citations
• Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice (2011) — 1,334 citations
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. (2010) — 1,247 citations
• Immunogenic death of colon cancer cells treated with oxaliplatin (2010) — 1,108 citations
• Immunological aspects of cancer chemotherapy (2008) — 949 citations
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) — 3,002 citations
• Calreticulin exposure dictates the immunogenicity of cancer cell death (2007) — 3,061 citations
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007) — 1,275 citations
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner (2005) — 877 citations
• Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation (2005) — 824 citations
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative (2004) — 998 citations